Ubrogepant

CAS Number1374248-77-7
Molecular FormulaC29H26F3N5O3
Molecular Weight549.5
InChI KeyDDOOFTLHJSMHLN-ZQHRPCGSSA-N
LogP3.1
Synonyms
  • Ubrogepant
  • 1374248-77-7
  • MK-1602
  • Ubrelvy
  • UNII-AD0O8X2QJR
  • AD0O8X2QJR
  • (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide
  • (3'S)-N-((3S,5S,6R)-6-Methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro(cyclopenta(b)pyridine-6,3'-pyrrolo(2,3-b)pyridine)-3-carboxamide
  • Ubrogepant [USAN:INN]
  • Ubrelvy (TN)
  • Ubrogepant (USAN/INN)
  • SCHEMBL3698428
  • CHEMBL2364638
  • GTPL10176
  • DTXSID00160178
  • EX-A3049
  • MFCD28386182
  • MK1602
  • ZINC95598454
  • AT16059
  • DB15328
  • AC-31965
  • HY-12366
  • CS-0011109
  • D10673
  • A934103
  • Q27273878
  • S-1374248-77-7
  • (6S)-N-[(3S,5S,6R)-6-Methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide
  • (S)-N-((3S,5S,6R)-6-Methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide
  • Spiro(6H-cyclopenta(b)pyridine-6,3'-(3H)pyrrolo(2,3-b)pyridine)-3-carboxamide, 1',2',5,7-tetrahydro-N-((3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl)-2'-oxo-, (3'S)-

Applications:

HPLC Method For Analysis Of Ubrogepant in UBRELVY® Tablets on Newcrom R1 Column

March 16, 2022

HPLC Method for Ubrogepant on Newcrom R1 by SIELC Technologies

High Performance Liquid Chromatography (HPLC) Method for Analysis of Ubrogepant.

Ubrogepant, also known as Ubrelvy®, is a newly discovered, calcitonin gene-related peptide receptor (CGPR) antagonist with the chemical formula C29H26F3N5O3. It is used for the acute treatment of migraine headaches. It is the first Calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.

Ubrogepant can be retained and analyzed using the Newcrom R1 stationary phase column. The analysis utilizes an isocratic method with a simple mobile phase consisting of water and acetonitrile (MeCN) with a sulfuric acid buffer. Detection is performed using UV.

Condition
Column Newcrom R1, 2.1 x 100 mm, 3 µm, 100 A, dual ended
Mobile Phase MeCN/H2O – 40/60%
Buffer H2SO4 – 0.1%
Flow Rate 0.2 ml/min
Detection UV 285 nm

Description
Class of Compounds Drug
Analyzing Compounds Ubrogepant

Application Column

Newcrom R1

Column Diameter: 2.1 mm
Column Length: 100 mm
Particle Size: 3 µm
Pore Size: 100 A
Column options: dual ended

Add to cart
Application Analytes:
Ubrogepant
Application Detection:
UV Detection
SIELC Technologies usually develops more than one method for each compound. Therefore, this particular method may not be the best available method from our portfolio for your specific application. Before you decide to implement this method in your research, please send us an email to research@sielc.com so we can ensure you get optimal results for your compound/s of interest.